WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentINTRODUCTION
Afficher le documentGLOSSARY
Fermer ce répertoire1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
Afficher le document1.1 Justification for the trial
Afficher le document1.2 Ethical principles
Afficher le document1.3 Supporting data for the investigational product
Afficher le document1.4 Investigator and site(s) of investigation
Afficher le document1.5 Regulatory requirements
Afficher le document2. THE PROTOCOL
Ouvrir ce répertoire et afficher son contenu3. PROTECTION OF TRIAL SUBJECTS
Ouvrir ce répertoire et afficher son contenu4. RESPONSIBILITIES OF THE INVESTIGATOR
Ouvrir ce répertoire et afficher son contenu5. RESPONSIBILITIES OF THE SPONSOR
Ouvrir ce répertoire et afficher son contenu6. RESPONSIBILITIES OF THE MONITOR
Ouvrir ce répertoire et afficher son contenu7. MONITORING OF SAFETY
Ouvrir ce répertoire et afficher son contenu8. RECORD KEEPING AND HANDLING OF DATA
Ouvrir ce répertoire et afficher son contenu9. STATISTICS AND CALCULATIONS
Ouvrir ce répertoire et afficher son contenu10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Ouvrir ce répertoire et afficher son contenu11. ROLE OF THE DRUG REGULATORY AUTHORITY
Afficher le document12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
Afficher le document13. CONSIDERATIONS FOR MULTICENTRE TRIALS
Afficher le documentREFERENCES
Afficher le documentAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
Afficher le documentAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

1.5 Regulatory requirements

Countries in which clinical trials are performed should have regulations governing the way in which these studies can be conducted. The pre-trial agreement between the sponsor and investigator(s) should designate the parties responsible for meeting each applicable regulatory requirement (e.g. application to or notification of the trial to the relevant authority, amendments to the trial protocol, reporting of all adverse events, and notifications to ethics committee). All parties involved in a clinical trial should comply fully with the existing national regulations or requirements. In countries where regulations do not exist or require supplementation, relevant government officials may designate, in part or in whole, these Guidelines as the basis on which clinical trials will be conducted. The use of these Guidelines should not prevent their eventual adaptation into national regulations or laws. Neither should they be used to supersede an existing national requirement in countries where the national requirement is more rigorous.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013